BAP1 – Inactivated Melanocytoma. Description of the Case and Overview of the Issue
Authors:
Z. Szép 1,2; N. Majtánová 3; J. Majtán 4,5
Authors place of work:
Katedra dermatovenerológie LF SZU a výučbové centrá Onkologický ústav sv. Alžbety s. r. o., Bratislava, a Dermatovenerologická klinika LF SZU a FNsP Trnava, vedúci katedry a prednosta kliniky doc. MUDr. Zoltán Szép, PhD., MPH
1; Unilabs Slovensko, s. r. o., Diagnostické centrum patológie, Bratislava, vedúca oddelenia prim. MUDr. Iveta Mečiarová, PhD.
2; Očná klinika LF SZU a UNB – pracovisko Nemocnica sv. Cyrila a Metoda, Bratislava, prednosta prof. MUDr. Petr Kolář, PhD.
3; Ústav molekulárnej biológie SAV, v. v. i., Bratislava, riaditeľka Ing. Eva Kutejová, DrSc.
4; Ústav mikrobiológie LF SZU, Bratislava, prednostka prof. RNDr. Shubhada Bopegamage, CSc.
5
Published in the journal:
Čes-slov Derm, 99, 2024, No. 3, p. 126-131
Category:
Case Reports
Summary
BAP1-inactivated melanocytoma is a rare melanocytic lesion that was first described by Thomas Wiesner in 2011. It belongs to the group of so-called melanocytomas, which represent a group of intermediate melanocytic lesions. It occurs mostly sporadically, but rarely it can be part of the so-called hereditary BAP1 tumor predisposition syndrome. We present the case of a 33-year-old woman with a solitary BAP1-inactivated melanocytoma.
Keywords:
melanocytoma – BAP1 – hereditary BAP1 tumor predisposition syndrome
Zdroje
- ANDEA, A. A. Molecular testing for melanocytic tumors: a practical update. Histopathology, 2022, 80(1), p. 150–165.
- CARBONE, M., FERRIS, L. K., BAUMANN, F. et al. BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med, 2012, 10, p. 179.
- DONATI, M., MARTINEK, P., STEINER, P. et al. Novel insights into the BAP1-inactivated melanocytic tumor. Mod Pathol, 2022, 35(5), p. 664–675.
- ELDER, D. E., BASTIAN, B. C., CREE, I. A., MASSI, D. et al. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med, 2020, 144(4), p. 500–522.
- FERNANDEZ-FLORES, A. Modern Concepts in Melanocytic Tumors. Actas Dermosifiliogr, 2023, 114(5), p. 402–412.
- FERRARA, G., MARIANI, M. P., AURIEMMA, M. BAP1-inactivated melanocytic tumour with borderline histopathological features (BAP1-inactivated melanocytoma): A case report and a reappraisal. Australas J Dermatol, 2021, 62(1): e88–e91.
- FOUCHARDIERE, A. D. L., BLOKX, W., KEMPEN, L. C. V. et al. ESP, EORTC, and EURACAN Expert Opinion: practical recommendations for the pathological diagnosis and clinical management of intermediate melanocytic tumors and rare related melanoma variants. Virchows Arch, 2021, 479(1), p. 3–11.
- LINOS, K., ATKINSON, A. E., YAN, S. et al. A case of molecularly confirmed BAP1 inactivated melanocytic tumor with retention of immunohistochemical expression: a confounding factor. J Cutan Pathol, 2020, 47(5), p. 856–859.
- MASOOMIAN, B., SHIELDS, J. A., SHIELDS, C. L. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol, 2018, 30(2), p. 102–109.
- URSO, C. Melanocytic Skin Neoplams: What Lesson From Genomic Abberations? Am J Dermatopathol, 2019, 41(9), p. 623–629.
- WHO Classification of Skin Tumours. 4. vyd., WHO, 2018. 500 s. ISBN 978-92-832-2440-2.
- WHO Classification of Skin Tumours. 5. vyd., WHO, 2023. Beta version ahead of print.
- WIESNER, T., OBENAUF, A. C., MURALI, R. et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet, 2011, 43(10), p. 1018–1021.
- YEH, I. Melanocytic nevi, melanocytomas and emerging concepts. Pathology, 2023, 55(2), p. 178–186.
- YEH, I. New and evolving concepts of melanocytic nevi and melanocytomas. Mod Pathol, 2020, 33, Suppl.1, p. 1–14.
- YEH, I. Update on classification of melanocytic tumors and the role of immunohistochemistry and molecular techniques. Semin Diagn Pathol, 2022, 39(4), p. 248–256.
- ZHANG, A. J., RUSH, P. S., TSAO, H. et al. BRCA1-associated protein (BAP1)-inactivated melanocytic tumors. J Cutan Pathol, 2019, 46(12), p. 965–972.
Do redakce došlo dne 6. 11. 2023.
Adresa pro korespondenci:
doc. MUDr. Zoltán Szép, PhD, MPH
Onkologický ústav sv. Alžbety
Heydukova 10
812 50 Bratislava
Slovenská republika
e-mail: zoltan.szep@ousa.sk
Štítky
Dermatology & STDs Paediatric dermatology & STDsČlánok vyšiel v časopise
Czech-Slovak Dermatology
2024 Číslo 3
Najčítanejšie v tomto čísle
- Hereditary Angioedema – Classification and Differential Diagnosis
- BAP1 – Inactivated Melanocytoma. Description of the Case and Overview of the Issue
- Nail Changes Lasting 30 Years
- CZECH AND SLOVAK DERMATOLOGY AND VENEREOLOGY